Kinnate Biopharma Inc.
KNTE · NASDAQ
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $112 | $66 | $141 | $284 |
| - Cash | $57 | $52 | $35 | $74 |
| + Debt | $3 | $3 | $4 | $4 |
| Enterprise Value | $58 | $18 | $111 | $214 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$19 | -$33 | -$34 | -$34 |
| % Margin | – | – | – | – |
| Net Income | -$17 | -$31 | -$32 | -$31 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.36 | -0.65 | -0.68 | -0.69 |
| % Growth | 44.6% | 4.4% | 1.4% | – |
| Operating Cash Flow | -$17 | -$26 | -$29 | -$28 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | -$17 | -$26 | -$29 | -$28 |